Showing 1021-1030 of 1321 results for "".
- Some Parents Just Don't Understand Risks of Indoor Tanninghttps://practicaldermatology.com/news/some-parents-just-dont-understand-risks-of-indoor-tanning/2457878/Dads, parents who had used indoor tanning devices themselves and those who reported that they had never received skin cancer prevention counseling from their child’s doctor are less likely to believe adolescent indoor tanning is harmful, a new survey shows. To investigate parents&rs
- Dr. Jacob Chacko Joins Bonti's Board of Directorshttps://practicaldermatology.com/news/dr-jacob-chacko-joins-bontis-board-of-directors/2457893/Jacob Chacko, MD has joined Bonti’s Board of Directors. Dr. Chacko has served as the Chief Financial Officer of Ignyta, Inc. since May 2014. At Ignyta, he leads multiple functions, including Finance, Accounting, Investor Relations, Communications
- Short Course Radiation Best Longer Courses in Older Skin Cancer Patientshttps://practicaldermatology.com/news/short-case-radiation-best-longer-courses-in-older-skin-cancer-patients/2457899/Shorter courses of radiation seem to be better than longer ones for older patients receiving treatment for basal and squamous cell skin cancers, a recent Penn State College of Medicine physician’s st
- Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in EBhttps://practicaldermatology.com/news/abeona-receives-fda-regenerative-medicine-advanced-therapy-designation-for-eb-101-gene-therapy-in-eb/2457908/The US Food and Drug Administration (FDA) granted the Regenerative Medicine Advanced Therapy (RMAT) designation to EB-101, Abeona Therapeutics Inc.’s gene-corrected autologous cell therapy product for patients with recessive dystrophic epidermolysis bullosa (RDEB). “EB-101 is
- Dr. Brandt Skincare Rolls Out Two New Productshttps://practicaldermatology.com/news/dr-brandt-skincare-rolls-out-two-new-products/2457909/Dr. Brandt skincare is introducing Hydro Biotic Recovery Sleeping Mask and Antioxidant Water Booster. The new sleeping mask is powered by Dr. Brandt Skincare's Biotic Balancing Complex, an oligosaccharide and yogurt powder that helps restore n
- Intraderm Changes Alevicyn Product Name to Levicynhttps://practicaldermatology.com/news/intraderm-changes-alevicyn-product-name-to-levicyn/2457910/Intraderm's Alevicyn is getting a new name—Levicyn. The Gel formulation is now Levicyn Antipruritic Gel, the Spray Gel is now Levicyn Antipruritic SG, and the Dermal Spray is now Levicyn Antimicrobial Dermal Spray. The company notes that physicians can still write for Alevicyn d
- Meet JAAD's New Editor Dirk M. Elston, MDhttps://practicaldermatology.com/news/meet-jaads-new-editor-dirk-m-elston-md/2457918/Charleston, SC-based dermatologist Dirk M. Elston, MD, FAAD, is the next editor of the Journal of the American Academy of Dermatology. Dr. Elston, the journal’s current deputy editor, will step into his new role in July 2018, succeeding de
- Maui Derm: New Data Validates First IGA Scale for EBS Clinical Trialshttps://practicaldermatology.com/news/maui-derm-new-data-validates-first-iga-scale-for-ebs-clinical-trials/2457923/Data from an evaluation of a completed Phase 2 study of diacerein 1% ointment (CCP-020) for the treatment of epidermolysis bullosa simplex (EBS) validate the first disease-specific Investigator’s Global Assessment (IGA) scale, Castle Creek Pharmaceuticals (CCP) reports at Maui Derm (
- Nailed It: Researchers Unveil Fingernail-Sized UV Sensor at CEShttps://practicaldermatology.com/news/nailed-it-researchers-unveil-fingernail-sized-uv-sensor-at-ces/2457931/Northwestern University researchers and L’Oréal have nailed it. Working together, they developed a wafer-thin, feather-light sensor can fit on a fingernail and precisely measures a person’s exposure to UV light from the sun. The device, as light as a raindrop an
- FDA Grants AbbVie's Upadacitinib Breakthrough Therapy Designation for Atopic Dermatitishttps://practicaldermatology.com/news/fda-grants-abbvies-upadacitinib-breakthrough-therapy-designation-for-atopic-dermatitis/2457932/The FDA granted Breakthrough Therapy Designation for AbbVie's investigational, once-daily oral JAK1-selective inhibitor upadacitinib (ABT-494) in adult patients with moderate to severe atopic dermatitis who are candidates for systemic therapy. This Breakthrough Therapy Designation is supporte